{"0": ["Aquatic Ecotoxicology", 0], "1": ["Serotonin Receptor Modulation in SSRI Treatment", 2], "2": ["Analytical Methods for SSRI Detection and Quantification", 2], "3": ["SSRIs for OCD", 1], "4": ["Risk of Prenatal Exposure", 1], "5": ["SSRIs for Pediatric Depression", 1], "6": ["SSRIs and the Cytochrome P450 System", 2], "7": ["Impact of SSRIs on Neurogenesis", 2], "8": ["The Chronic Unpredictable Mild Stress Model of Depression", 1], "9": ["SSRIs Effect on Neural Processing of Emotional Cues", 1], "10": ["Risk of Prenatal Exposure (Rodents)", 1], "11": ["SSRIs for PTSD", 2], "12": ["SSRIs in Forced Swimming Test", 2], "13": ["SSRI Utilization Patterns", 1], "14": ["Fluvoxamine for Depression", 1], "15": ["Inflammatory Biomarkers", 1], "16": ["Sexual Dysfunction", 1], "17": ["SSRIs Effect on Fear", 2], "18": ["Post-Stroke SSRI Use", 1], "19": ["Escitalopram for Depression", 1], "20": ["Serotonin Transporter Gene and Antidepressant Response", 1], "21": ["Treatment Strategies and Outcomes in Depression", 1], "22": ["SSRIs for Pain", 1], "23": ["SSRIs for Depression in Patients with Cardiovascular Disease", 1], "24": ["SSRIs in Dementias", 1], "25": ["Serotonin Syndrome", 1], "26": ["SSRIs for Weight Management", 1], "27": ["Paroxetine Binding to Serotonin Transporter", 2], "28": ["Bleeding Risk", 1], "29": ["Antidepressant-like Effects of Herbal Extracts in Animal Models", 2], "30": ["Oncopreventive and Oncolytic Properties of SSRIs", 1], "31": ["Suicice Risk", 1], "32": ["Fracture Risk", 1], "33": ["SSRIs for Generalized Anxiety Disorder", 1], "34": ["SSRIs for Panic Disorder", 1], "35": ["Pharmacological Reviews", 2], "36": ["SSRIs for Bipolar Depression", 1], "37": ["Hepatotoxic Risk", 2], "38": ["Fluvoxamine for Covid 19", 1], "39": ["Pharmacoeconomics of SSRIs for Depression", 0], "40": ["SSRIs Effect on Sleep", 1], "41": ["Venlafaxine vs SSRIs for Depression", 1], "42": ["SSRI Effects on Lactation", 1], "43": ["SSRIs for Depression in Diabetes Patients", 1], "44": ["SSRIs for Menopausal Vasomotor Symptoms (Hot flashes)", 1], "45": ["Pharmacovigilance of SSRIs", 1], "46": ["Premature Ejaculation", 1], "47": ["SSRIs for Depression with Cognitive Impairment", 1], "48": ["QTC Prolongation", 1], "49": ["Extrapyramidal Reactions Risk", 1], "50": ["SSRIs for Irritable Bowel Syndrome", 1], "51": ["SSRIs for Alcohol Dependence", 1], "52": ["SSRIs for Premenstrual Dysphoric Disorder (PMDD)", 1], "53": ["Neuroimaging of Serotonin Transporters", 2], "54": ["SSRIs for (Psycho)dermatological Diseases", 1], "55": ["Synthetic Chemistry of Paroxetine", 2], "56": ["SSRIs for Autism Spectrum Disorders", 1], "57": ["SSRIs for Eating Disorders", 1], "58": ["SSRIs for Depression in Parkinsons Patients", 1], "59": ["SSRIs for Depression in in Epileptic Patients", 1], "60": ["SSRIs Effects on Ion Channels", 2], "61": ["SSRIs and Augmentation for Treatment Resistant Depression", 1], "62": ["Environmental Degradation of Antidepressants", 0], "63": ["Methylenedioxymethamphetamine (MDMA) Induced Neurotoxicity", 2], "64": ["Laboratory Techniques for drug analysis", 2], "65": ["SSRIs for Social Anxiety Disorder", 1], "66": ["Forensic Toxicology of Fatal Overdoses", 0], "67": ["SSRIs (Fluvoxamine) for Schizophrenia", 1], "68": ["SSRIs Effect on Pulmonary Hypertension", 2], "69": ["SSRIs for Body Dysmorphic Disorder (BDD)", 1], "70": ["Antidepressant Drug Design", 2], "71": ["Serotonergic Modulation of Cocaine Effects", 2], "72": ["Pharmacogenetics in SSRI Treatment", 2], "73": ["Non-SERT Transporters in Antidepressant Action", 2], "74": ["SSRIs for Depression, Comparative Effectiveness", 1], "75": ["SSRIs for Geriatric Depression", 1], "76": ["SERT Binding Mechanisms", 2], "77": ["Astrocyte Receptors as a Target for SSRIs", 2], "78": ["SSRIs for Borderline Personality Disorder", 1], "79": ["Agomelatin for Depression", 1], "80": ["Depression Treatment Guidelines", 1], "81": ["Sertraline for Depression", 1], "82": ["Withdrawal Symptoms", 1], "83": ["Hyponatremia Risk", 1], "84": ["SSRIs Effect on Dopamine Receptors", 2], "85": ["SSRIs Effects on Antimicrobials and Gut Microbiome", 2], "86": ["SSRIs for Depression after Traumatic Brain Injury", 1], "87": ["Antifungal Activity of Sertraline", 2], "88": ["Neurometabolite Changes with Antidepressants", 1], "89": ["Galanin System in Antidepressant Action", 2], "90": ["SSRIs for Fibromyalgia", 1], "91": ["SSRI Crystal Structure and Complexation", 2], "92": ["SSRIs Effect on Brain-derived Neurotrophic Factor (BDNF) Levels in Depressive Patients", 1], "93": ["SSRIs in Model Organisms ( C. Elegans and Drosophilia)", 2], "94": ["SSRIs for Depression in Cancer Patients", 1], "95": ["SSRIs for Postpartum Depression", 1], "96": ["SSRIs Long-term Efficacy and Recurrent Depression", 1], "97": ["Canine Behavioral Disorders", 0], "98": ["Gatways to Clinical Trials", 9], "99": ["SRRIs and Ocular Safety", 1], "100": ["Folate for Depression", 1], "101": ["SSRIs for Depression in Patients with Kidney Disease", 1], "102": ["Psilocybin for Depression", 1], "103": ["SSRIs Effect on Reinforcement Learning in Rodents", 2], "104": ["SSRIs for Behavioral Addictions", 1], "105": ["St. John's Wort for Depression", 1], "106": ["SSRIs for Migraine", 1], "107": ["Vilazodone for Depression", 1], "108": ["SSRIs for Dysthymia", 1], "109": ["SSRIs for Enuresis", 1], "110": ["Paroxetines as G Protein-coupled Receptor Kinase 2 (GRK2) Inhibitor", 2], "111": ["SSRIs for Trichotillomania", 1], "112": ["Transcranial Direct Current Stimulation (tDCS) for Depression", 1], "113": ["SSRIs for Burning Mouth Syndrome", 1], "114": ["SSRIs for Depression in Patients with Chronic Obstructive Pulmonary Disease (COPD)", 1], "115": ["SSRIs for the Mangement of Multiple Sclerosis", 1], "116": ["SSRIs for Interferon-Induced Depression", 1], "117": ["SSRIs for Depression in HIV-positive Patients", 1], "118": ["Acupuncture for Depression", 1], "119": ["SSRIs for Syncope", 1], "120": ["SSRIs for Smoking Cessation", 1], "121": ["Loudness Dependence of Auditory Evoked Potentials (LDAEP) as Biomarker for Depression", 2], "122": ["SSRIs for Tinnitus ", 1], "123": ["Exercise for Depression", 1], "124": ["SSRI-Methylphenidate Interactions", 2], "125": ["SSRIs for Narcolepsy", 1], "126": ["SSRIs for OCD-like behaviors", 2], "127": ["SSRIs in the Treatment of Huntington Disease", 1], "128": ["SSRIs for Congenital Myasthenic Syndrome (SCCMS)", 1], "129": ["Tryptophan Depletion in Depression", 1], "130": ["Risk of Microscopic Colitis", 1], "131": ["Herbal Remedies for SSRI-Induced Sexual Dysfunction", 2], "132": ["Adulterants of SSRIs in Weight Loss Supplements", 2], "133": ["SSRIs for Mutism", 1], "134": ["SSRIs for Tourette's Syndrome", 1], "135": ["Childhood Trauma and Antidepressant Response", 1], "136": ["SSRIs Risk of Apathy syndrome", 1], "137": ["Serotonin Transporter in Primate Models", 2], "138": ["Blood-Brain Barrier Drug Transport", 2], "139": ["Polypharmacy Effects in Aging Models", 2], "140": ["Gateways to Clinical Trials", 9], "141": ["SSRIs for Infertile Women", 1], "142": ["Fewer than 10", 9], "143": ["Fewer than 10", 9]}